Petros Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
PTPI$0.07-46.5%Stored close · as of May 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | |
| 3.1 | | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 2, 2025). |
| 3.2 | | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 11, 2025). |
| 3.3 | | Certificate of Amendment to the Certificate of Designations of Series A Convertible Preferred Stock of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2.4 to the Company’s Annual Report on Form 10-K filed on March 31, 2025). |
| 3.4 | | Certificate of Designations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1/A filed on February 13, 2025). |
| | | |
| 4.1 | | Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8 - K filed on February 21, 2025). |
| 4.2 | | Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8 - K filed on February 21, 2025). |
| 4.3 | | Form of Pre - Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8 - K filed on February 21, 2025). |
| 10.1# | | Third Amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 11, 2025). |
| 10.2 | | Form of Amendment Agreement, dated January 23, 2025, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 24, 2025). |
| 10.3 | | Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.22 to the Company’s registration statement on Form S-1/A filed on February 10, 2025). |
| 10.4 | | Form of Securities Purchase Agreement, dated February 17, 2025, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 - K filed on February 21, 2025). |
| 10.5 | | Termination Agreement, dated as of March 31, 2025, by and between Vivus LLC and Metuchen Pharmaceuticals LLC (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed on March 31, 2025). |
| 10.6 | | Form of Amendment Agreement, dated March 30, 2025, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K filed on March 31, 2025). |
| 10.7# | | Second Amendment to Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (incorporated by reference to Exhibit 10.23 to the Company’s registration statement on Form S-1/A filed on February 10, 2025). |
| 31.1* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer. |
| 31.2* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer. |
| 32** | | Section 1350 Certification – Principal Executive Officer and Principal Financial Officer. |
| 101 | | The following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Consolidated Financial Statements. |
| 104 | | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
| # | Management contract or compensatory plan or arrangement. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.